Indoco Remedies · NSE: INDOCO · BSE: 532612
Q4 FY25 results · Jan–Mar 2025
Indoco Remedies reported revenue from operations of ₹390.21 crore (down 13.2% from Q4 FY24) and net loss of ₹41.34 crore for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 390.21 | 449.64 | −13.2% | 410.55 | −5.0% |
| Other income | 2.02 | 2.66 | −24.1% | 0.85 | +137.6% |
| Total income | 392.23 | 452.30 | −13.3% | 411.40 | −4.7% |
| Profit before tax | (45.52) | 32.98 | Turned loss | (30.96) | Loss widened |
| Net profit for the period | (41.34) | 22.03 | Turned loss | (28.40) | Loss widened |
| Attributable to shareholders of the company | (40.39) | 22.70 | Turned loss | (26.39) | Loss widened |
| EPS, basic (₹) | (4.48) | 2.39 | Turned loss | (3.08) | Loss widened |
| Net margin (%) | -10.6 | 4.9 | -6.9 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 347.25 | 445.49 | −22.1% | 372.98 | −6.9% |
| Other income | 6.50 | 4.05 | +60.5% | 4.26 | +52.6% |
| Total income | 353.75 | 449.54 | −21.3% | 377.24 | −6.2% |
| Profit before tax | (30.90) | 46.50 | Turned loss | (13.36) | Loss widened |
| Net profit for the period | (26.24) | 37.56 | Turned loss | (10.23) | Loss widened |
| EPS, basic (₹) | (2.85) | 4.08 | Turned loss | (1.11) | Loss widened |
| Net margin (%) | -7.6 | 8.4 | -2.7 |
Consolidated
- Filed with BSE
- 22 May 2025, 17:43 IST
- Board meeting
- 22 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 22 May 2025, 17:43 IST
- Board meeting
- 22 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE